Akoya Biosciences Company Insiders

AKYA Stock  USD 2.11  0.01  0.47%   
Akoya Biosciences' insiders are aggressively selling. The analysis of insiders' sentiment of trading Akoya Biosciences stock suggests that vertually all insiders are panicking at this time. Akoya Biosciences employs about 330 people. The company is managed by 15 executives with a total tenure of roughly 770 years, averaging almost 51.0 years of service per executive, having 22.0 employees per reported executive.

Akoya Biosciences' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-06-11Brian MckelligonDisposed 7500 @ 2.08View
2024-06-06Brian MckelligonDisposed 7500 @ 2.01View
2024-03-20Brian MckelligonDisposed 7500 @ 4.97View
2024-03-13Brian MckelligonDisposed 7500 @ 4.94View
2023-12-19Brian MckelligonDisposed 7500 @ 4.48View
Monitoring Akoya Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

Akoya Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.1809) % which means that it has lost $0.1809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.282) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, Akoya Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 59.4 M, whereas Total Assets are forecasted to decline to about 157.2 M.
As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 42.6 M. The current year's Net Loss is expected to grow to about (60.4 M)

Akoya Biosciences Workforce Comparison

Akoya Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 50,092. Akoya Biosciences maintains roughly 330 in number of employees contributing less than 1% to equities under Health Care industry.

Akoya Biosciences Profit Margins

The company has Profit Margin (PM) of (0.65) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.47) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.47.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.660.5827
Moderately Up
Slightly volatile

Akoya Biosciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akoya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akoya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Akoya Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
0.2
1
5
 40,000 
 240,000 
2024-06-01
1.6
8
5
 315,000 
 44,272 
2024-03-01
0.9286
13
14
 1,067,092 
 436,120 
2023-12-01
0.8333
5
6
 82,500 
 45,000 
2023-06-01
8.0
16
2
 2,802,642 
 10,000 
2023-03-01
2.0
16
8
 947,750 
 55,327 
2022-12-01
0.2857
4
14
 279,613 
 401,147 
2022-09-01
0.2
1
5
 5,000 
 42,296 
2022-06-01
4.3333
13
3
 561,146 
 10,000 
2022-03-01
5.0
5
1
 372,500 
 0.00 
2021-12-01
2.5
5
2
 68,573 
 25,100 
2021-09-01
1.0
1
1
 38,993 
 0.00 
2021-06-01
0.3158
6
19
 119,862 
 1,145,858 

Akoya Biosciences Notable Stakeholders

An Akoya Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Akoya Biosciences often face trade-offs trying to please all of them. Akoya Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Akoya Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brian McKelligonCEO PresidentProfile
Pascal BamfordResearch PresidentProfile
John EkPrincipal CFOProfile
Clifford HoytVP AffairsProfile
Marilee MBAChief OfficerProfile
Jennifer KamocsayGeneral CounselProfile
Nikolay SamusikCoFounderProfile
Priyam ShahSenior StrategyProfile
JD CFASecretaryProfile
Niro RamachandranChief OfficerProfile
Yury GoltsevCoFounderProfile
Joseph DriscollChief OfficerProfile
Garry NolanIndependent CoFounderProfile
Paul GrassSenior SalesProfile
Frederic PlaChief OfficerProfile

About Akoya Biosciences Management Performance

The success or failure of an entity such as Akoya Biosciences often depends on how effective the management is. Akoya Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Akoya management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Akoya management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.44)(0.46)
Return On Capital Employed(0.40)(0.42)
Return On Assets(0.35)(0.37)
Return On Equity(1.18)(1.24)
Please note, the presentation of Akoya Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akoya Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Akoya Biosciences' management manipulating its earnings.

Akoya Biosciences Workforce Analysis

Traditionally, organizations such as Akoya Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Akoya Biosciences within its industry.

Akoya Biosciences Manpower Efficiency

Return on Akoya Biosciences Manpower

Revenue Per Employee292.8K
Revenue Per Executive6.4M
Net Loss Per Employee191.9K
Net Loss Per Executive4.2M
Working Capital Per Employee262K
Working Capital Per Executive5.8M

Complementary Tools for Akoya Stock analysis

When running Akoya Biosciences' price analysis, check to measure Akoya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akoya Biosciences is operating at the current time. Most of Akoya Biosciences' value examination focuses on studying past and present price action to predict the probability of Akoya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akoya Biosciences' price. Additionally, you may evaluate how the addition of Akoya Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance